Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Proactive Investors One2One Investor Forum - London

Arix Bioscience Plc | Avacta Group Plc | Silence Therapeutics plc

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception. Details on the presenting companies can be found below.


This event is suitable for the following:

Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.


The event is not suitable for people pursuing commercial opportunities.

Arix Bioscience Plc

RSS Portfolio


Arix Bioscience is a global healthcare and life science company that drives value in private and public companies through operational and strategic direction as well as patient capital.

Led by renowned figures in the healthcare and life science sectors, Arix Bioscience is headquartered in London and has an office in New York.

Our extensive experience in academic science, clinical and commercial strategy, company operations, mergers and acquisitions, venture capital and corporate finance puts us in an especially strong position to build and support a wide range of businesses and technologies.

Arix Bioscience has privileged agreements with leading universities in the UK, Europe and Australia, providing direct access to innovative new technologies. We also have access to a broad range of research projects from US academic institutions.

Market: LSE
52-week High/Low: 220.00p / 156.00p
Market Cap: 237.96M

View full company profile

Avacta Group Plc

RSS Portfolio


Avacta’s principal focus is on its proprietary Affimer® platform, a novel engineered alternative to antibodies that has wide application in diagnostics, therapeutics and research.

Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer proteins, which can be quickly generated to bind with high specificity and affinity to a wide range of targets, have been designed to address these negative performance issues. 

Avacta has a pre-clinical drug development programme with a primary focus on immuno-oncology as well as partnered development programmes. Avacta is also commercialising non-therapeutic Affimer reagents through licensing to developers of research tools and diagnostics.

Market: AIM
52-week High/Low: 73.70p / 21.00p
Market Cap: 30.02M

View full company profile

Silence Therapeutics plc

RSS Portfolio


We are a drug development company with a proprietary genetic medicine platform

Our technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells.  This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo.

We have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics. This allows the development of therapeutics for diseases with high unmet clinical need. Silence’s technology is currently in the clinic in a Phase 2a pancreatic cancer trial.

Silence Therapeutics is traded in the NEX Exchange HERE

Market: AIM
52-week High/Low: 254.75p / 110.00p
Market Cap: 92.67M

View full company profile

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use